Merck wins expanded OK for shingles vax; Amgen to unveil Xgeva data;

@FiercePharma: Does Steere's exit signal a new day at Pfizer? News | Follow @FiercePharma

> The FDA has approved expanded use of Zostavax, a shingles vaccine made by Merck, to people 50 to 59 years old; it was already approved for use in people 60 years and older. Report

> Amgen will present full results of a key study of its bone drug Xgeva at a meeting of the American Urological Association on May 17, providing important clues about the drug's sales potential. News

> Mylan has announced that its subsidiary UDL Laboratories struck a license agreement with Humeca, a leading plastic surgery and burn treatment products company, for exclusive U.S. distribution rights to Humeca products. Story

> Walgreen's announcement that it plans to purchase the web business drugstore.com for $409 million highlights the radically different business strategies of the nation's two leading drugstore chains. Report

> A U.S. Court has upheld a Cephalon patent protecting its Fentora pain medicine in a dispute with generic drugmaker Watson Pharmaceuticals. News

> The board of directors of Hungarian drugmaker Gedeon Richter proposed an 860 forint dividend at an annual general meeting on April 27. Item

Biotech News

@FierceBiotech:  Fresh delay for Novartis's indacaterol app. Article | Follow @FierceBiotech 

@JohnCFierce: Israel's Protalix looking to file on two more drugs by '16--Fabry disease and RA. Report | Follow @JohnCFierce 

> Sanofi inks vision, diabetes deals. News

> Fledging biotech AltheRx nabs Ph3 urology program from GSK. Item

> Cancer drug developer MethylGene raises $34.5M. Story

> Study: Pfizer pancreatic cancer drug shrinks tumors. Article

And Finally... Men with high-risk prostate cancer who take statin drugs while receiving radiation therapy are less likely to have their cancer return than patients who do not take these medications, according to a study. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.